Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Depreciation & Amortization (CF) (2020 - 2024)

Immuneering (IMRX) has 5 years of Depreciation & Amortization (CF) data on record, last reported at $86116.0 in Q4 2024.

  • For Q4 2024, Depreciation & Amortization (CF) fell 4.05% year-over-year to $86116.0; the TTM value through Dec 2024 reached $355807.0, up 10.22%, while the annual FY2024 figure was $355807.0, 10.22% up from the prior year.
  • Depreciation & Amortization (CF) reached $86116.0 in Q4 2024 per IMRX's latest filing, down from $88949.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $90533.0 in Q2 2024 and bottomed at $5656.0 in Q3 2020.
  • Average Depreciation & Amortization (CF) over 5 years is $54603.5, with a median of $72301.0 recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 468.33% in 2022, then fell 4.05% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $5656.0 in 2020, then surged by 161.93% to $14815.0 in 2021, then soared by 418.81% to $76862.0 in 2022, then rose by 16.77% to $89754.0 in 2023, then decreased by 4.05% to $86116.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $86116.0 in Q4 2024, $88949.0 in Q3 2024, and $90533.0 in Q2 2024.